Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 19

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 1
Chunk 19
---
 difficult, or in some cases not possible, for investors in the United States to enforce their legal rights, to effect service of process upon Mr. Chu or to enforce judgments of United States courts predicated upon civil liabilities and criminal penalties on him under United States securities laws.

 15Table of Contents

Our stock price may be volatile and your investment in our common stock could suffer a decline in value.

Because our common stock is on the Expert Market, there is no market for our common stock. There can be no assurance that any significant market, or any market, will ever develop in our common stock when we are current in our SEC filings and cease to be on the Expert Market. Because of the low public float and the lack of trading volume, any reported prices may not reflect the price at which you would be able to sell shares if you want to sell any shares you own or buy shares if you wish to buy shares. Further, stocks with a low public float may be more subject to manipulation than a stock that has a significant public float. The price may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include, but are not limited to, the following, in addition to the risks described above and general market and economic conditions:

 ·our low stock price, which may result in a modest dollar purchase or sale of our common stock having a disproportionately large effect on the stock price; ·the market’s perception as to our ability to generate revenue and positive cash flow or earnings; ·changes in our or securities analysts’ estimate of our financial performance; ·our ability or perceived ability to obtain necessary financing for our operations and the anticipated dilution that would result from any sales of our equity securities; ·the perception of the future market for our products and whether we will be successful in developing and marketing our chicken feed or any other product; ·the anticipated or actual results of our operations; ·changes in market valuations of other natural supplement companies; ·any discrepancy between anticipated or projected results and actual results of our operations; ·actions by third parties to either sell or purchase stock in quantities which would have a significant effect on our stock price; and ·other factors not within our control.

Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.

If we were to raise additional capital by issuing equity securities, either alone or in connection with a non-equity financing